Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Edwards to Buy Innovalve, an Early-Stage TMVR Company - Medical Product Outsourcing

What are you searching for?

Sign in
Financial & Business, OEM News

Edwards to Buy Innovalve, an Early-Stage TMVR Company

Edwards initially invested in Innovalve in 2017, which included an option to acquire.

Author Image

By: Sam Brusco

Associate Editor

Edwards Lifesciences has exercised its option to acquire Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement (TMVR) company.

Edwards initially invested in Innovalve in 2017. Since then, Innovalve has had promising early clinical experience in its program.

The acquisition boosts the company’s TMVR technologies to address the large unmet structural heart patient population. Innovalve will join Edwards’ transcatheter mitral and tricuspid (TMTT) franchise, which is led by corporate VP Daveen Chopra.

Last week, Edwards announced it had received Health Canada approval for its Pascal Precision transcatheter valve repair system for percutaneous reduction of significant, symptomatic mitral regurgitation.

The deal for Innovalve is anticipated to close by the end of this year.

“Building on our learnings of the complexity of mitral disease, we know there is a need for a differentiated range of therapies for these patients,” said Chopra. “Edwards’ SAPIEN M3 remains on track to become the first approved transfemoral TMVR system in Europe by the end of 2025. We believe the Innovalve technologies, paired with Edwards’ deep mitral expertise, will enable a TMVR platform that will expand the treatable population.”

This month, Edwards also revealed it had struck several deals totaling €15 million with French clinical-stage firm Affluent Medical. The agreements relate to Affluent’s Kalios adjustable mitral annulus as well as mitral valve technology.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Add Medical Product Outsourcing as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters

Topics